Cuidados com o paciente Diabético
Diabetic patient care
DOI:
https://doi.org/10.34117/bjdv8n9-169Keywords:
Diabetes, controle glicêmico, complicação vascularesAbstract
As metas de hemoglobina glicada (A1C) em pacientes com diabetes tipo 2 devem ser adaptadas ao indivíduo, equilibrando a melhora das complicações microvasculares com o risco de hipoglicemia. Uma meta razoável da terapia pode ser um valor de A1C ≤ 7% para a maioria dos pacientes. As metas glicêmicas geralmente são definidas um pouco mais altas para pacientes com histórico de hipoglicemia grave, pacientes com expectativa de vida limitada, crianças muito pequenas ou adultos mais velhos e indivíduos com comorbidades. Melhor controle glicêmico melhora o risco de complicações microvasculares em pacientes com diabetes tipo 2. O tratamento intensivo da glicose no sangue está associado a um risco aumentado de hipoglicemia, bem como a sobrecarga de polifarmácia, efeitos colaterais adicionais e custo. Dependendo dos agentes prescritos, o ganho de peso também pode ocorrer com o tratamento intensivo.
References
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977.
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.
Wei N, Zheng H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care 2014; 37:1048.
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44:S73.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577.
Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376:419.
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103.
ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560.
Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:1392.
ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233.
Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care 2019; 42:416.
Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375:481.
